Cartalax (AED peptide)

Bioregulatory Tripeptide | Cartilage & Connective Tissue Support

Weight: ~350 Da
Half-life: Minutes (short peptide); effects persist via epigenetic changes
Chain: 3 amino acids
4 studies
Emerging
Dose 100-200mcg oral (1-2 capsules) or 700-1400mcg injectable
Frequency 1-2 times daily with meals (oral) or once daily (injectable)
Cycle 1-3 months depending on application
Storage Oral capsules: room temperature; Injectable lyophilized: 2-8°C; Reconstituted: 2-8°C refrigerated

Community Research

Join others researching Cartalax — share findings, ask questions, and learn from real experiences

View Results Aggregated community findings
Discussion Questions & experiences
Submit Your Findings Contribute your research data

Synthetic tripeptide developed by Professor Vladimir Khavinson, supporting cartilage, connective tissue, and cellular regeneration through proliferation markers and apoptosis pathway modulation.

Mechanism of Action

Modulates cell proliferation, suppresses apoptosis, affects fibroblast activity, reduces senescence markers, and influences extracellular matrix preservation.

01 Joint and connective tissue support
02 Potential anti-aging effects on fibroblasts
03 Cartilage regeneration support
04 Established safety profile in Russian clinical practice

Molecular Data

Molecular Weight
~350 Da
Chain Length
3 amino acids
Type
Tripeptide
Amino Acid Sequence
One-letter: AE?
H₂N
A 1
O ‖ C
N
E 2
O ‖ C
N
H
? 3
COOH
Ala
1

Alanine

Position 1

Glu
2

Glutamic Acid

Position 2

Asp
3

Asp (AED)

Position 3

N-terminus C-terminus
Hydrophobic
Polar
Positive (+)
Negative (-)
Modified

Research Indications

Joint Health
Osteoarthritis effective

Clinical efficacy shown in osteochondrosis, osteoarthritis, and osteoporosis treatment.

Degenerative Joint Disease Prevention moderate

Supports cartilage maintenance and joint function.

Post-Fracture Recovery moderate

Supports bone and connective tissue healing.

Skin Health
Fibroblast Activation effective

Increased Ki-67 expression with suppressed apoptosis in young and aged cells.

Collagen Production effective

Enhances collagen synthesis in connective tissue.

Cellular Senescence Reduction moderate

Inhibited MMP-9 synthesis; maintained extracellular matrix integrity.

Dosing Protocols

Capsule form; do not chew, swallow whole with water during meals.

GoalDoseFrequencyRoute
Joint Support100-200mcg (1-2 capsules)1-2x daily with mealsOral

Interactions

++
Other Khavinson Peptides
Complementary bioregulatory effects across organ systems.
synergistic
++
Collagen Supplements
May enhance synthesis while supplements provide raw materials.
synergistic
+
BPC-157
Different mechanisms; no direct interaction.
compatible
+
TB-500
Distinct action pathways; may complement effects.
compatible
~
Growth Factors (IGF-1, GH)
Both affect tissue growth; monitor for excessive proliferation.
monitor
++
Glucosamine/Chondroitin
Complementary joint support mechanisms.
synergistic

What to Expect

Week 1-2
Establishing baseline; minimal noticeable changes
Week 3-4
Gradual improvement in joint comfort
Month 2
Noticeable mobility improvements
Month 3
Maximum therapeutic effect achieved

Side Effects & Safety

Common Side Effects

  • No reported side effects in Russian clinical use when taken properly
  • Well-tolerated in elderly patients

Stop Signs - Discontinue if:

  • Allergic reactions
  • Digestive upset (rare with proper administration)
  • No improvement after 3 months
  • Unexpected symptoms

Contraindications

  • Pregnancy and breastfeeding
  • Active cancer (theoretical proliferation risk)

Quality Checklist

Good Signs

  • Professional Russian packaging with holographic seals
  • Exactly 0.1mg (100mcg) AC-4 peptide complex per capsule
  • Clear Russian/English instructions specifying 'with meals'

Warning Signs

  • Proper documentation required for authenticity
  • Import verification needed

Bad Signs

  • Missing holographic seals or professional packaging
  • Unclear dosing instructions

References

  • Fibroblast Proliferation Study
    (2019)

    Human skin fibroblasts; 72 hours at 20 nM. Increased Ki-67 expression with suppressed apoptosis in young and aged cells.

  • Kidney Cell Culture Research
    (2020)

    Renal epithelial cells; 7 days. Reduced pro-apoptotic p53 expression in aging kidney cells.

  • Clinical Spine & Joint Study (Russia)
    (N/A)

    Human subjects; 1-3 months with 0.1mg capsules daily. Efficacy in osteochondrosis, osteoarthritis, and osteoporosis treatment.

  • Matrix Metalloproteinase Research
    (2020)

    Fibroblast cultures; 5 days at 20 nM. Inhibited MMP-9 synthesis; maintained extracellular matrix integrity.

Related Peptides

BPC-157 compatible

Different mechanisms; no direct interaction.

TB-500 compatible

Distinct action pathways; may complement effects.

Disclaimer

This information is for educational and research purposes only. Consult a healthcare professional before use.